Clinical Trial: A multicenter, randomized, double-blind, parallel-controlled, dose-range Phase II clinical study to evaluate the efficacy and safety of VB19055 in participants with uncontrolled hypertension (including refractory hypertension) after treatment with two or more antihypertensive drugs (China)

China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A multicenter, randomized, double-blind, parallel-controlled, dose-range Phase II clinical study to evaluate the efficacy and safety of VB19055 in participants with uncontrolled hypertension (including refractory hypertension) after treatment with two or more antihypertensive drugs'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129811

Registration Time: 2026/08/10

Type: Interventional study

Primary Sponsor: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=336138

Published by HT Digital ...